1
|
Sawaki D, Zhang Y, Mohamadi A, Pini M, Mezdari Z, Lipskaia L, Naushad S, Lamendour L, Altintas DM, Breau M, Liang H, Halfaoui M, Delmont T, Surenaud M, Rousseau D, Yoshimitsu T, Louache F, Adnot S, Henegar C, Gual P, Czibik G, Derumeaux G. Osteopontin promotes age-related adipose tissue remodeling through senescence-associated macrophage dysfunction. JCI Insight 2023; 8:145811. [PMID: 37092554 DOI: 10.1172/jci.insight.145811] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2020] [Accepted: 03/03/2023] [Indexed: 04/25/2023] Open
Abstract
Adipose tissue macrophages (ATMs) play an important role in obesity and inflammation, and they accumulate in adipose tissue (AT) with aging. Furthermore, increased ATM senescence has been shown in obesity-related AT remodeling and dysfunction. However, ATM senescence and its role are unclear in age-related AT dysfunction. Here, we show that ATMs (a) acquire a senescence-like phenotype during chronological aging; (b) display a global decline of basic macrophage functions such as efferocytosis, an essential process to preserve AT homeostasis by clearing dysfunctional or apoptotic cells; and (c) promote AT remodeling and dysfunction. Importantly, we uncover a major role for the age-associated accumulation of osteopontin (OPN) in these processes in visceral AT. Consistently, loss or pharmacologic inhibition of OPN and bone marrow transplantation of OPN-/- mice attenuate the ATM senescence-like phenotype, preserve efferocytosis, and finally restore healthy AT homeostasis in the context of aging. Collectively, our findings implicate pharmacologic OPN inhibition as a viable treatment modality to counter ATM senescence-mediated AT remodeling and dysfunction during aging.
Collapse
Affiliation(s)
- Daigo Sawaki
- INSERM U955, Université Paris-Est Créteil, Créteil, France
| | - Yanyan Zhang
- INSERM U955, Université Paris-Est Créteil, Créteil, France
| | - Amel Mohamadi
- INSERM U955, Université Paris-Est Créteil, Créteil, France
| | - Maria Pini
- INSERM U955, Université Paris-Est Créteil, Créteil, France
| | - Zaineb Mezdari
- INSERM U955, Université Paris-Est Créteil, Créteil, France
| | | | - Suzain Naushad
- INSERM U955, Université Paris-Est Créteil, Créteil, France
| | | | | | - Marielle Breau
- INSERM U955, Université Paris-Est Créteil, Créteil, France
| | - Hao Liang
- INSERM U955, Université Paris-Est Créteil, Créteil, France
| | | | - Thaïs Delmont
- INSERM U955, Université Paris-Est Créteil, Créteil, France
| | - Mathieu Surenaud
- INSERM U955, Université Paris-Est Créteil, Créteil, France
- AP-HP Vaccine Research Institute, Créteil, France
| | | | - Takehiko Yoshimitsu
- Laboratory of Synthetic Organic and Medicinal Chemistry, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama, Japan
| | - Fawzia Louache
- Université Paris-Saclay, Inserm UMR-S-MD1197, Hôpital Paul Brousse, Villejuif, France
- Gustave Roussy Cancer Center, Villejuif, France
| | - Serge Adnot
- INSERM U955, Université Paris-Est Créteil, Créteil, France
- AP-HP, Department of Physiology, Henri Mondor Hospital, FHU SENEC, Créteil, France
| | | | - Philippe Gual
- Université Côte d'Azur, INSERM U1065, C3M, Nice, France
| | - Gabor Czibik
- INSERM U955, Université Paris-Est Créteil, Créteil, France
| | - Geneviève Derumeaux
- INSERM U955, Université Paris-Est Créteil, Créteil, France
- AP-HP, Department of Physiology, Henri Mondor Hospital, FHU SENEC, Créteil, France
| |
Collapse
|
2
|
Altintas DM, Gallo S, Basilico C, Cerqua M, Bocedi A, Vitacolonna A, Botti O, Casanova E, Rancati I, Milanese C, Notari S, Gambardella G, Ricci G, Mastroberardino PG, Boccaccio C, Crepaldi T, Comoglio PM. The PSI Domain of the MET Oncogene Encodes a Functional Disulfide Isomerase Essential for the Maturation of the Receptor Precursor. Int J Mol Sci 2022; 23:ijms232012427. [PMID: 36293286 PMCID: PMC9604360 DOI: 10.3390/ijms232012427] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2022] [Revised: 09/28/2022] [Accepted: 10/13/2022] [Indexed: 11/29/2022] Open
Abstract
The tyrosine kinase receptor encoded by the MET oncogene has been extensively studied. Surprisingly, one extracellular domain, PSI, evolutionary conserved between plexins, semaphorins, and integrins, has no established function. The MET PSI sequence contains two CXXC motifs, usually found in protein disulfide isomerases (PDI). Using a scrambled oxidized RNAse enzymatic activity assay in vitro, we show, for the first time, that the MET extracellular domain displays disulfide isomerase activity, abolished by PSI domain antibodies. PSI domain deletion or mutations of CXXC sites to AXXA or SXXS result in a significant impairment of the cleavage of the MET 175 kDa precursor protein, abolishing the maturation of α and β chains, of, respectively, 50 kDa and 145 kDa, disulfide-linked. The uncleaved precursor is stuck in the Golgi apparatus and, interestingly, is constitutively phosphorylated. However, no signal transduction is observed as measured by AKT and MAPK phosphorylation. Consequently, biological responses to the MET ligand—hepatocyte growth factor (HGF)—such as growth and epithelial to mesenchymal transition, are hampered. These data show that the MET PSI domain is functional and is required for the maturation, surface expression, and biological functions of the MET oncogenic protein.
Collapse
Affiliation(s)
- Dogus Murat Altintas
- IFOM, FIRC Institute for Molecular Oncology, Via Adamello 16, 20139 Milano, Italy
- Correspondence: (D.M.A.); (P.M.C.)
| | - Simona Gallo
- Department of Oncology, University of Turin, 10060 Candiolo, Italy
- Candiolo Cancer Institute, FPO-IRCCS, Strada Provinciale 142, 10060 Candiolo, Italy
| | | | - Marina Cerqua
- IFOM, FIRC Institute for Molecular Oncology, Via Adamello 16, 20139 Milano, Italy
| | - Alessio Bocedi
- Department of Chemical Sciences and Technologies, University of Rome “Tor Vergata”, 00133 Rome, Italy
| | - Annapia Vitacolonna
- Department of Oncology, University of Turin, 10060 Candiolo, Italy
- Candiolo Cancer Institute, FPO-IRCCS, Strada Provinciale 142, 10060 Candiolo, Italy
| | - Orsola Botti
- IFOM, FIRC Institute for Molecular Oncology, Via Adamello 16, 20139 Milano, Italy
| | - Elena Casanova
- Candiolo Cancer Institute, FPO-IRCCS, Strada Provinciale 142, 10060 Candiolo, Italy
| | - Ilaria Rancati
- IFOM, FIRC Institute for Molecular Oncology, Via Adamello 16, 20139 Milano, Italy
| | - Chiara Milanese
- IFOM, FIRC Institute for Molecular Oncology, Via Adamello 16, 20139 Milano, Italy
| | - Sara Notari
- Department of Chemical Sciences and Technologies, University of Rome “Tor Vergata”, 00133 Rome, Italy
| | - Giorgia Gambardella
- Department of Chemical Sciences and Technologies, University of Rome “Tor Vergata”, 00133 Rome, Italy
| | - Giorgio Ricci
- Department of Chemical Sciences and Technologies, University of Rome “Tor Vergata”, 00133 Rome, Italy
| | - Pier Giorgio Mastroberardino
- IFOM, FIRC Institute for Molecular Oncology, Via Adamello 16, 20139 Milano, Italy
- Department of Life, Health, and Environmental Sciences, University of L’Aquila, 67100 L’Aquila, Italy
| | - Carla Boccaccio
- Department of Oncology, University of Turin, 10060 Candiolo, Italy
- Candiolo Cancer Institute, FPO-IRCCS, Strada Provinciale 142, 10060 Candiolo, Italy
| | - Tiziana Crepaldi
- Department of Oncology, University of Turin, 10060 Candiolo, Italy
- Candiolo Cancer Institute, FPO-IRCCS, Strada Provinciale 142, 10060 Candiolo, Italy
| | - Paolo Maria Comoglio
- IFOM, FIRC Institute for Molecular Oncology, Via Adamello 16, 20139 Milano, Italy
- Correspondence: (D.M.A.); (P.M.C.)
| |
Collapse
|
3
|
Czibik G, Mezdari Z, Murat Altintas D, Bréhat J, Pini M, d'Humières T, Delmont T, Radu C, Breau M, Liang H, Martel C, Abatan A, Sarwar R, Marion O, Naushad S, Zhang Y, Halfaoui M, Suffee N, Morin D, Adnot S, Hatem S, Yavari A, Sawaki D, Derumeaux G. Dysregulated Phenylalanine Catabolism Plays a Key Role in the Trajectory of Cardiac Aging. Circulation 2021; 144:559-574. [PMID: 34162223 DOI: 10.1161/circulationaha.121.054204] [Citation(s) in RCA: 31] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Aging myocardium undergoes progressive cardiac hypertrophy and interstitial fibrosis with diastolic and systolic dysfunction. Recent metabolomics studies shed light on amino acids in aging. The present study aimed to dissect how aging leads to elevated plasma levels of the essential amino acid phenylalanine and how it may promote age-related cardiac dysfunction. METHODS We studied cardiac structure and function, together with phenylalanine catabolism in wild-type (WT) and p21-/- mice (male; 2-24 months), with the latter known to be protected from cellular senescence. To explore phenylalanine's effects on cellular senescence and ectopic phenylalanine catabolism, we treated cardiomyocytes (primary adult rat or human AC-16) with phenylalanine. To establish a role for phenylalanine in driving cardiac aging, WT male mice were treated twice a day with phenylalanine (200 mg/kg) for a month. We also treated aged WT mice with tetrahydrobiopterin (10 mg/kg), the essential cofactor for the phenylalanine-degrading enzyme PAH (phenylalanine hydroxylase), or restricted dietary phenylalanine intake. The impact of senescence on hepatic phenylalanine catabolism was explored in vitro in AML12 hepatocytes treated with Nutlin3a (a p53 activator), with or without p21-targeting small interfering RNA or tetrahydrobiopterin, with quantification of PAH and tyrosine levels. RESULTS Natural aging is associated with a progressive increase in plasma phenylalanine levels concomitant with cardiac dysfunction, whereas p21 deletion delayed these changes. Phenylalanine treatment induced premature cardiac deterioration in young WT mice, strikingly akin to that occurring with aging, while triggering cellular senescence, redox, and epigenetic changes. Pharmacological restoration of phenylalanine catabolism with tetrahydrobiopterin administration or dietary phenylalanine restriction abrogated the rise in plasma phenylalanine and reversed cardiac senescent alterations in aged WT mice. Observations from aged mice and human samples implicated age-related decline in hepatic phenylalanine catabolism as a key driver of elevated plasma phenylalanine levels and showed increased myocardial PAH-mediated phenylalanine catabolism, a novel signature of cardiac aging. CONCLUSIONS Our findings establish a pathogenic role for increased phenylalanine levels in cardiac aging, linking plasma phenylalanine levels to cardiac senescence via dysregulated phenylalanine catabolism along a hepatic-cardiac axis. They highlight phenylalanine/PAH modulation as a potential therapeutic strategy for age-associated cardiac impairment.
Collapse
Affiliation(s)
- Gabor Czibik
- INSERM (L'Institut National de la Santé et de la Recherche Médicale) U955 (G.C., Z.M., D.M.A., J.B., M.P., T.d'H., T.D., C.R., M.B., H.L., A.A., O.M., S.N., Y.Z., M.H., D.M., S.A., D.S., G.D.), Université Paris-Est Créteil, France
- Department of Physiology (G.C., T.d'H., S.A., G.D.), AP-HP, Henri Mondor Hospital, FHU-SENEC, Créteil, France
| | - Zaineb Mezdari
- INSERM (L'Institut National de la Santé et de la Recherche Médicale) U955 (G.C., Z.M., D.M.A., J.B., M.P., T.d'H., T.D., C.R., M.B., H.L., A.A., O.M., S.N., Y.Z., M.H., D.M., S.A., D.S., G.D.), Université Paris-Est Créteil, France
| | - Dogus Murat Altintas
- INSERM (L'Institut National de la Santé et de la Recherche Médicale) U955 (G.C., Z.M., D.M.A., J.B., M.P., T.d'H., T.D., C.R., M.B., H.L., A.A., O.M., S.N., Y.Z., M.H., D.M., S.A., D.S., G.D.), Université Paris-Est Créteil, France
| | - Juliette Bréhat
- INSERM (L'Institut National de la Santé et de la Recherche Médicale) U955 (G.C., Z.M., D.M.A., J.B., M.P., T.d'H., T.D., C.R., M.B., H.L., A.A., O.M., S.N., Y.Z., M.H., D.M., S.A., D.S., G.D.), Université Paris-Est Créteil, France
| | - Maria Pini
- INSERM (L'Institut National de la Santé et de la Recherche Médicale) U955 (G.C., Z.M., D.M.A., J.B., M.P., T.d'H., T.D., C.R., M.B., H.L., A.A., O.M., S.N., Y.Z., M.H., D.M., S.A., D.S., G.D.), Université Paris-Est Créteil, France
| | - Thomas d'Humières
- INSERM (L'Institut National de la Santé et de la Recherche Médicale) U955 (G.C., Z.M., D.M.A., J.B., M.P., T.d'H., T.D., C.R., M.B., H.L., A.A., O.M., S.N., Y.Z., M.H., D.M., S.A., D.S., G.D.), Université Paris-Est Créteil, France
- Department of Physiology (G.C., T.d'H., S.A., G.D.), AP-HP, Henri Mondor Hospital, FHU-SENEC, Créteil, France
| | - Thaïs Delmont
- INSERM (L'Institut National de la Santé et de la Recherche Médicale) U955 (G.C., Z.M., D.M.A., J.B., M.P., T.d'H., T.D., C.R., M.B., H.L., A.A., O.M., S.N., Y.Z., M.H., D.M., S.A., D.S., G.D.), Université Paris-Est Créteil, France
| | - Costin Radu
- INSERM (L'Institut National de la Santé et de la Recherche Médicale) U955 (G.C., Z.M., D.M.A., J.B., M.P., T.d'H., T.D., C.R., M.B., H.L., A.A., O.M., S.N., Y.Z., M.H., D.M., S.A., D.S., G.D.), Université Paris-Est Créteil, France
- Department of Cardiac Surgery (C.R.), AP-HP, Henri Mondor Hospital, FHU-SENEC, Créteil, France
| | - Marielle Breau
- INSERM (L'Institut National de la Santé et de la Recherche Médicale) U955 (G.C., Z.M., D.M.A., J.B., M.P., T.d'H., T.D., C.R., M.B., H.L., A.A., O.M., S.N., Y.Z., M.H., D.M., S.A., D.S., G.D.), Université Paris-Est Créteil, France
| | - Hao Liang
- INSERM (L'Institut National de la Santé et de la Recherche Médicale) U955 (G.C., Z.M., D.M.A., J.B., M.P., T.d'H., T.D., C.R., M.B., H.L., A.A., O.M., S.N., Y.Z., M.H., D.M., S.A., D.S., G.D.), Université Paris-Est Créteil, France
| | - Cecile Martel
- Mitologics SAS (C.M.), Université Paris-Est Créteil, France
| | - Azania Abatan
- INSERM (L'Institut National de la Santé et de la Recherche Médicale) U955 (G.C., Z.M., D.M.A., J.B., M.P., T.d'H., T.D., C.R., M.B., H.L., A.A., O.M., S.N., Y.Z., M.H., D.M., S.A., D.S., G.D.), Université Paris-Est Créteil, France
| | - Rizwan Sarwar
- Experimental Therapeutics, Radcliffe Department of Medicine (R.S., A.Y.), University of Oxford, United Kingdom
| | - Ophélie Marion
- INSERM (L'Institut National de la Santé et de la Recherche Médicale) U955 (G.C., Z.M., D.M.A., J.B., M.P., T.d'H., T.D., C.R., M.B., H.L., A.A., O.M., S.N., Y.Z., M.H., D.M., S.A., D.S., G.D.), Université Paris-Est Créteil, France
| | - Suzain Naushad
- INSERM (L'Institut National de la Santé et de la Recherche Médicale) U955 (G.C., Z.M., D.M.A., J.B., M.P., T.d'H., T.D., C.R., M.B., H.L., A.A., O.M., S.N., Y.Z., M.H., D.M., S.A., D.S., G.D.), Université Paris-Est Créteil, France
| | - Yanyan Zhang
- INSERM (L'Institut National de la Santé et de la Recherche Médicale) U955 (G.C., Z.M., D.M.A., J.B., M.P., T.d'H., T.D., C.R., M.B., H.L., A.A., O.M., S.N., Y.Z., M.H., D.M., S.A., D.S., G.D.), Université Paris-Est Créteil, France
| | - Maissa Halfaoui
- INSERM (L'Institut National de la Santé et de la Recherche Médicale) U955 (G.C., Z.M., D.M.A., J.B., M.P., T.d'H., T.D., C.R., M.B., H.L., A.A., O.M., S.N., Y.Z., M.H., D.M., S.A., D.S., G.D.), Université Paris-Est Créteil, France
| | - Nadine Suffee
- Sorbonne Universités, INSERM UMR_S1166, Faculté de Médecine UPMC, Paris, France (N.S., S.H.)
- Institute of Cardiometabolism and Nutrition, ICAN, Paris, France (N.S., S.H.)
| | - Didier Morin
- INSERM (L'Institut National de la Santé et de la Recherche Médicale) U955 (G.C., Z.M., D.M.A., J.B., M.P., T.d'H., T.D., C.R., M.B., H.L., A.A., O.M., S.N., Y.Z., M.H., D.M., S.A., D.S., G.D.), Université Paris-Est Créteil, France
| | - Serge Adnot
- INSERM (L'Institut National de la Santé et de la Recherche Médicale) U955 (G.C., Z.M., D.M.A., J.B., M.P., T.d'H., T.D., C.R., M.B., H.L., A.A., O.M., S.N., Y.Z., M.H., D.M., S.A., D.S., G.D.), Université Paris-Est Créteil, France
- Department of Physiology (G.C., T.d'H., S.A., G.D.), AP-HP, Henri Mondor Hospital, FHU-SENEC, Créteil, France
| | - Stéphane Hatem
- Sorbonne Universités, INSERM UMR_S1166, Faculté de Médecine UPMC, Paris, France (N.S., S.H.)
- Institute of Cardiometabolism and Nutrition, ICAN, Paris, France (N.S., S.H.)
| | - Arash Yavari
- Experimental Therapeutics, Radcliffe Department of Medicine (R.S., A.Y.), University of Oxford, United Kingdom
- Wellcome Centre for Human Genetics (A.Y.), University of Oxford, United Kingdom
| | - Daigo Sawaki
- INSERM (L'Institut National de la Santé et de la Recherche Médicale) U955 (G.C., Z.M., D.M.A., J.B., M.P., T.d'H., T.D., C.R., M.B., H.L., A.A., O.M., S.N., Y.Z., M.H., D.M., S.A., D.S., G.D.), Université Paris-Est Créteil, France
| | - Geneviève Derumeaux
- INSERM (L'Institut National de la Santé et de la Recherche Médicale) U955 (G.C., Z.M., D.M.A., J.B., M.P., T.d'H., T.D., C.R., M.B., H.L., A.A., O.M., S.N., Y.Z., M.H., D.M., S.A., D.S., G.D.), Université Paris-Est Créteil, France
- Department of Physiology (G.C., T.d'H., S.A., G.D.), AP-HP, Henri Mondor Hospital, FHU-SENEC, Créteil, France
| |
Collapse
|